Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach.
PMID 17010196 · PMC1592491 · BMC genomics · 2006 · 8 claims · 7 setups
High-throughput 454 sequencing-by-synthesis of LNCaP cDNA can profile transcript abundance across the transcriptome
-
Full-text index only
Evolutionarily conserved human targets of adenosine to inosine RNA editing.
PMID 15731336 · PMC549564 · Nucleic acids research · 2005 · 8 claims · 6 setups
Identified four novel human ADAR editing substrates causing amino acid changes: FLNA, BLCAP, CYFIP2 and IGFBP7
-
Full-text index only
FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.
PMID 41621066 · PMC13050545 · Cell reports · 2026 · 8 claims · 8 setups
FOXA1 mutations in a 874-tumor cohort cluster into missense, in-frame indel, and truncation subgroups, with indels concentrated at residues M253/E255
-
Full-text index only
Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.
PMID 42193276 · PMC13203762 · Biomedicines · 2026 · 8 claims · 8 setups
PARPi + ARPi combinations are effective in ARPi-sensitive (C4-2B) and ARPi-resistant (AbiR, MDVR) prostate cancer models, but provide the greatest benefit in ARPi-sensitive cells
-
Has reproduction · 68
Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients.
PMID 35012625 · PMC8743438 · Genome biology · 2022 · 8 claims · 9 setups
GENEVA (Gene Expression Variance Analysis) is a semi-automated framework that mines large-scale public RNA-seq datasets to identify conditions associated with a gene's expression variance
-
Full-text index only
Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer.
PMID 41710887 · PMC12909565 · Frontiers in immunology · 2026 · 8 claims · 8 setups
Higher EZH2 expression is associated with adverse clinical outcomes in bulk PCa/CRPC cohorts